



Attorney Docket No.: 6246.200-US

PATENT

1632  
#7  
JDS

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: P. Serup et al

Serial No.: 10/090,011

Group Art Unit: To be assigned

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on December 10, 2002.

Rashida Haji  
(name of person mailing paper)

Rashida Haji  
(signature of person mailing paper)

**RECEIVED**  
DEC 16 2002  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: P. Serup et al

Application No.: 10/090,011

Group Art Unit: To be assigned

Filed: February 26, 2002

Examiner: To be assigned

Confirmation No: 3868

For: Methods for Generating Insulin-Secreting Cells Suitable For Transplantation

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

**RECEIVED**

**DEC 16 2002**

**TECH CENTER 1600/2900**

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

1. WO 00 59936 A
2. US Patent 5,695,995
3. Jensen et al, Diabetes, NY, Vol. 49, No. 2, Pages 163-176, (2000)
4. Grapin - Botton et al, Genes & Development, Vol.15, Pages 444-454, (2001).

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **before** the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: December 10, 2002

Richard W. Bork  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800



23650

PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. <b>6246.200-US</b>	Serial No. <b>10/090,011</b>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant <b>P. Serup et al</b>	
(Use several sheets if necessary)		Filing Date <b>February 26, 2002</b>	Group <b>To be assigned</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,695,995	12/9/1997	Weintraub et al	435	325	11/2/95
						
						
						
						
						
						
						
						
						

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Jensen et al. Diabetes, NY, Vol. 49, No. 2, Pages 163-176, (2000)  
Grapin-Botton et al. Genes & Development, Vol. 15, Pages 444-454, (2001)

RECEIVED  
DEC 16 2002  
TECH CENTER 1600/2900

RECEIVED

DEC 16 2002

## TECH CENTER 1600/2900

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.